The ORR with pamiparib plus tislelizumab in the urothelial cancer cohort in the present study (28.6%) also appeared encouraging, and was similar to findings reported in the phase III KEYNOTE-045 trial of pembrolizumab as second-line therapy for advanced urothelial cancer (21.1%) [49] and in a phase II trial of tislelizumab in Asian patients with previously treated advanced PD-L1-positive urothelial carcinoma (24.0%) [33]. The gene discussed is CD274; the disease is urothelial carcinoma.